Drug-induced liver injury network (DILIN) prospective study: Rationale, design and conduct

Drug Safety

Volumn 32, Issue 1, 2009, Pages 55-68

  Fontana, Robert J ^a,j   Watkins, Paul B ^b   Bonkovsky, Herbert L ^b,c,d,e   Chalasani, Naga ^f   Davern, Timothy ^g   Serrano, Jose ^h   Rochon, James ⁱ  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c Carolinas Center for Liver Disease   (United States)

^d CAROLINAS MEDICAL CENTER   (United States)

^e UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^f INDIANA UNIVERSITY   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

ⁱ DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^j UNIVERSITY OF MICHIGAN   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DRUG;

ARTICLE; CAUSAL ATTRIBUTION; CHRONICITY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG RESEARCH; FOLLOW UP; HUMAN; LIVER INJURY; MAJOR CLINICAL STUDY; NOMENCLATURE; PATIENT SELECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; REGISTER; RISK FACTOR; SCORING SYSTEM;

FOLLOW-UP STUDIES; HUMANS; LIVER DISEASES; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES (U.S.); PHARMACEUTICAL PREPARATIONS; PROSPECTIVE STUDIES; REGISTRIES; RESEARCH DESIGN; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TERMINOLOGY AS TOPIC; UNITED STATES;

EID: 58149347349     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200932010-00005     Document Type: Article

References (47)

1. Ostapowicz G, Fontana RJ, Schiodt RV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002; 137: 947-54
2. Lee WM, Senior JR. Recognizing drug-induced liver injury: current problems, possible solutions. Toxciol Pathol 2005; 33: 155-64
3. Favreau JT, Ryu ML, Braunstein G, et al. Severe hepatoxicity associated with the dietary supplement Lipokinetix. Ann Intern Med 2002; 136: 590-5
4. Stickel F, Baumuller HM, Seitz K, et al. Hepatitis induced by Kava (Piper methysticum rhizome). J Hepatol 2003; 39: 62-7
5. Bjornson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology 2005; 42: 481-9
6. Watkins PB, Seeff LB. Drug induced liver injury: summary of a single topic clinical research conference. Hepatology 2006; 43: 618-31
7. Walgren JL, Mitchell MD, Thompson DC. Role of metabolism in drug-induced idiosyncratic hepatotoxicity. Crit Rev Toxicol 2005; 35: 325-61
8. Navarro VJ, Senior JR. Drug related hepatotoxicity. N Engl J Med 2006; 354: 731-9
9. Andrade RJ, Lucena I, Alonso A, et al. HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease. Hepatology 2004; 39: 1603-12
10. Kaplowitz N. Causality assessment versus guilt-by-association in drug hepatotoxicity. Hepatology 2001; 33: 308-10
11. Verma A, Lilienfeld DE. The need for a population-based surveillance system for liver disease in the United States. Pharmacoepidemiol Drug Saf 2004; 13: 821-4
12. Hoofnagle JH. Drug induced liver injury network (DILIN). Hepatology 2004; 40: 773
13. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Med Care 1992; 30: 473-83
14. Varni JW, Burwinkle TM, Seid M, et al. The PedsQL 4.0 as a pediatric population health measure: feasibility, reliability, and validity. Ambul Pediatr 2003; 3: 329-41
15. Nunez M, Soriano V. Hepatotoxicity of antiretrovirals: incidence, mechanisms, and management. Drug Saf 2005; 38: 53-66
16. Ogedegbe AO, Sulkowski MS. Antiretroviral-associated liver injury. Clin Liver Dis 2003; 7: 475-99
17. Ioannou GN, Boyko EJ, Lee SP. The prevalence and predictors of elevated serum aminotransferase activity in the United States in 1999-2002. Am J Gastroenterol 2006; 101: 76-82
18. Aithal PG, Day CP. The natural history of histologically proved drug induced liver disease. Gut 1999; 44: 731-5
19. Kleiner DA, Chalasani NP, Conjeevaram HS, et al. Relationship of biochemical to histologic findings and the pathological pattern of injury among cases identified in the NIH drug induced liver injury network (DILIN) study [abstract]. Gastroenterology 2007; 132: M1775
20. Andrade RJ, Lucerna MI, Fernandez MC, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005; 129: 512-21
21. Shapiro MZ, Lewis JH. Causality assessment of drug-induced hepatotoxicity: promises and pitfalls. Clin Liver Dis 2007; 11: 477-505
22. Danan G, Benichou C. Causality assessment of adverse reactions to drugs: a novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993; 46: 1323-30
23. Chalasani N, Fontana RJ, Bonkovsky HL, for the Drug Induced Liver Injury Network (DILIN). Causes, clinical features, and outcomes from a prospective study of drug induced liver injury in the United States. Gastroenterology. Epub 2008 Sep 17
24. Hunter DJ, Kraft P. Drinking from the fire hose: statistical issues in genome-wide association studies. N Engl J Med 2007; 357: 436-9
25. Ballet F. Hepatotoxicity in drug development: detection, significance and solutions. J Hepatol 1997; 26 Suppl. 2: 26-36
26. Fontana RJ, McCashland TM, Benner KG, et al. Acute liver failure associated with prolonged use of bromfenac leading to liver transplantation. Liver Transpl Surg 1999; 5: 480-4
27. Graham DJ, Green L, Senior JR, et al. Troglitazone-induced liver failure: a case study. Am J Med 2003; 114: 299-306
28. Lee WM, Larrey D, Olsson R, et al. Hepatic findings in long-term clinical trials of ximelagatran. Drug Saf 2005; 28: 351-70
29. Wysowski DK, Swartz L. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002. Arch Intern Med 2005; 165: 1363-9
30. Devalle MB, Klinteberg AV, Alem N, et al. Drug induced liver injury in a Swedish University hospital outpatient hepatology clinic. Aliment Pharmacol Ther 2006; 24: 1187-95
31. Galan M, Potts J, Silverman AL, et al. The burden of acute non-fulminant drug-induced hepatitis in a United States Tertiary care center. J Clin Gastroenterol 2005; 39: 64-7
32. Sgro C, Clinard F, Ouazir K, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 2002; 36: 451-5
33. Whitehead MW, Hainsworth I, Kingham JGC. The cause of obvious jaundice in South West Wales: perceptions versus reality. Gut 2001; 48: 409-13
34. Ibanez L, Perez E, Vidal X, et al. Prospective surveillance of acute serious liver disease unrelated to infectious obstructive or metabolic diseases: epidemiological and clinical features, and exposure to drugs. J Hepatology 2002; 37: 592-600
35. Rumack BH. Acetaminophen hepatotoxicity: the first 35 years. J Toxicol Clin Toxicol 2002; 40: 3-20
36. LaRusso NF, Schneider BL, Black D, et al. Primary sclerosing cholangitis: summary of a workshop. Hepatology 2006; 44: 746-64
37. Patel PA, Voigt MD. Prevalence and interaction of hepatitis B and latent tuberculosis in Vietnamese immigrants to the United States. Am J Gastroenterol 2002; 97: 1198-203
38. Mok MY, Ng WL, Yuen MF, et al. Safety of disease modifying anti-rheumatic agents in rheumatoid arthritis patients with chronic viral hepatitis. Clin Exp Rheumatol 2000; 18: 363-8
39. Benichou C. Criteria of drug-induced liver disorders: report of an international consensus meeting. J Hepatol 1990; 11: 272-6
40. Andrade RJ, Lucena MI, Kaplowitz N, et al. Outcome of acute idiosyncratic drug-induced liver injury: long-term follow-up in a hepatotoxicity registry. Hepatology 2006; 44: 1581-8
41. Lok ASF, McMahon B. AASLD practice guideline: chronic hepatitis B. Hepatology 2007; 45: 507-39
42. Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 2006; 130: 231-64
43. Sharp JR, Ishak KG, Zimmerman HJ. Chronic active hepatitis and severe hepatic necrosis associated with nitrofurantoin. Ann Intern Med 1980; 92: 14-9
44. Shergy WJ, Polisson RP, Caldwell DS, et al. Methotrexate-associated hepatotoxicity: retrospective analysis of 210 patients with rheumatoid arthritis. Am J Med 1988; 85: 771-4
45. Rockey DC, Seeff LB, Freston JW, et al. Comparison between expert opinion and RUCAM for assignment of causality in drug induced liver injury [abstract]. Gastroenterology 2007; 132: M1777
46. Rochon J, Protiva B, Seeff LB, for the Drug Induced Liver Injury Network. The reliability of the RUCAM for assessing causality in drug-induced liver injury. Hepatology 2008; 48: 1175-83
47. Krivoy N, Taeri M, Neuman MG. Antiepileptic drug-induced hypersensitivity syndrome reactions. CNS Drugs 2004; 18: 5-25